

Resource Summary Report

Generated by [nidm-terms](#) on Jul 28, 2026

EMIF

RRID:SCR_010495

Type: Tool

Proper Citation

EMIF (RRID:SCR_010495)

Resource Information

URL: <http://www.emif.eu/>

Proper Citation: EMIF (RRID:SCR_010495)

Description: A project that aims to improve access to human health data by developing a common information framework (EMIF-Platform) that allows for efficient re-use of existing health data, opening up new avenues of research for scientists. To ensure immediate applicability, the project includes two specific therapeutic research topics: the onset of Alzheimer's Disease (EMIF-AD) and metabolic complications of obesity (EMIF-Metabolics). The AD Topic aims to discover and validate biomarkers of AD onset in the preclinical and prodromal phase as well as for disease progression and identify high-risk individuals for therapeutic trials for prevention. The Metabolic Topic aims to discover and evaluate biomarkers for the risk of metabolic complications in obesity and to identify high-risk populations for intervention purposes. Collaboration between the 3 topics will ensure the development and delivery of an efficient Information Framework. This initiative has combined several data sets for neuroimaging including ADNI and several others, curating them into transmart.

Abbreviations: EMIF

Synonyms: European Medical Information Framework

Resource Type: portal, consortium, data or information resource, organization portal

Keywords: metabolic complication, biomarker, tool development, data sharing, health data, preclinical, prodromal, interoperability, adult human, pediatric, young human, cell model, animal model, therapeutic target, trial design, high-risk population, metabolic, health, platform, prevention, clinical trial, disease progression

Funding: EFPIA ;
Innovative Medicines Initiative 115372

Resource Name: EMIF

Resource ID: SCR_010495

Alternate IDs: nlx_158040

Record Creation Time: 20220129T080259+0000

Record Last Update: 20260728T043338+0000

Ratings and Alerts

No rating or validation information has been found for EMIF.

No alerts have been found for EMIF.

Data and Source Information

Source: [SciCrunch Registry](#)

Usage and Citation Metrics

We found 45 mentions in open access literature.

Listed below are recent publications. The full list is available at [nidm-terms](#) .

Luckett ES, et al. (2025) Harmonizing genotype array data to understand genetic risk for brain amyloid burden in the AMYPAD PNHS Consortium. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(9), e70376.

Mathew S, et al. (2025) Retinal vascular biomarkers in mild cognitive impairment and Alzheimer's disease: a comprehensive review and meta-analysis. *Alzheimer's & dementia (Amsterdam, Netherlands)*, 17(2), e70132.

van Gils V, et al. (2025) The association of diabetes with Alzheimer's disease biomarkers and vascular burden across European aging and memory clinic cohorts. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(10), e70804.

Rikken RM, et al. (2025) Characterizing visual read tau-PET-negative participants with Alzheimer's disease dementia. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 21(4), e14423.

Weiner S, et al. (2025) Cerebrospinal fluid proteome profiling across the Alzheimer's disease continuum: a step towards solving the equation for 'X'. *Molecular neurodegeneration*, 20(1), 52.

Vaudano E, et al. (2025) The Innovative Health Initiative public-private partnership: a catalyst for big data-driven health research and innovation. *Frontiers in medicine*, 12, 1554948.

Beran M, et al. (2024) Biomarkers of endothelial dysfunction and cognition: A two-step IPD meta-analysis. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(12),

Delvenne A, et al. (2024) CSF proteomic profiles of neurodegeneration biomarkers in Alzheimer's disease. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(9), 6205.

Moonen JEF, et al. (2024) Contributions of amyloid beta and cerebral small vessel disease in clinical decline. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(3), 1868.

Smith RG, et al. (2024) Blood DNA methylomic signatures associated with CSF biomarkers of Alzheimer's disease in the EMIF-AD study. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(10), 6722.

Koetsier J, et al. (2024) Blood-based multivariate methylation risk score for cognitive impairment and dementia. *Alzheimer's & dementia : the journal of the Alzheimer's Association*, 20(10), 6682.

Sohn H, et al. (2023) Deportations and departures: Undocumented Mexican immigrants' return migration during three presidential administrations. *Proceedings of the National Academy of Sciences of the United States of America*, 120(9), e2212184120.

Pereira A, et al. (2022) Semantic Data Visualisation for Biomedical Database Catalogues. *Healthcare (Basel, Switzerland)*, 10(11).

Neumann A, et al. (2022) Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. *Molecular psychiatry*, 27(4), 1990.

Konijnenberg E, et al. (2021) Onset of Preclinical Alzheimer Disease in Monozygotic Twins. *Annals of neurology*, 89(5), 987.

Brito MF, et al. (2021) Scientific Advances in Diabetes: The Impact of the Innovative Medicines Initiative. *Frontiers in medicine*, 8, 688438.

Collij LE, et al. (2021) White matter microstructure disruption in early stage amyloid pathology. *Alzheimer's & dementia (Amsterdam, Netherlands)*, 13(1), e12124.

Aerts H, et al. (2021) Quality of Hospital Electronic Health Record (EHR) Data Based on the International Consortium for Health Outcomes Measurement (ICHOM) in Heart Failure: Pilot Data Quality Assessment Study. *JMIR medical informatics*, 9(8), e27842.

Pelkmans W, et al. (2021) Amyloid-??, cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. *Annals of clinical and translational neurology*, 8(2), 348.

van de Kreeke JA, et al. (2021) Longitudinal retinal layer changes in preclinical Alzheimer's disease. *Acta ophthalmologica*, 99(5), 538.